Actively Recruiting
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-01-13
164
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
CONDITIONS
Official Title
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- Body mass index (BMI) greater than 24 and less than 45 kg/m2
- Diagnosed with type 2 diabetes according to World Health Organization criteria (1999)
- Newly diagnosed type 2 diabetes with HbA1c ≥ 9.0% or uncontrolled type 2 diabetes (HbA1c ≥ 7.5%) treated with at least two oral hypoglycemic drugs at sufficient doses, or insulin (excluding basal-bolus therapy), or insulin with oral hypoglycemic drugs
- Signed informed consent
You will not qualify if you...
- History of pancreatic disease
- History of medullary thyroid carcinoma
- Lipase level more than 3 times above normal
- Creatinine clearance ≤ 30 mL/min/1.73m2
- Significant heart disease or stroke within the last 6 months, including myocardial infarction, unstable angina, coronary bypass, percutaneous coronary angioplasty, congestive heart failure (NYHA Class III-IV), or severe ischemic heart disease
- Currently pregnant or preparing for pregnancy
- Any factors considered by researchers to affect participation in the trial
- Unable to cooperate in clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The first afilliated hospital of Xiamen university
Xiamen, Fujian, China, 361003
Actively Recruiting
Research Team
C
Changqin Liu, MD
CONTACT
X
Xin Zheng, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here